Literature DB >> 16728967

Cabergoline treatment in men with psychogenic erectile dysfunction: a randomized, double-blind, placebo-controlled study.

M Nickel1, D Moleda, T Loew, W Rother, F Pedrosa Gil.   

Abstract

The effectiveness of cabergoline in 50 men with psychogenic erectile dysfunction was investigated in a 4-month, randomized, placebo-controlled, double-blind study with validated psychological tests, and prolactin, follicle-stimulating hormone, luteinizing hormone and testosterone serum levels. Cabergoline treatment was well-tolerated and resulted in normalization of hormone levels in most cases. In the cabergoline-treated group, significant interactions between prolactin and testosterone serum concentrations were observed. Erectile function improved significantly. Sexual desire, orgasmic function, and the patient's and his partner's sexual satisfaction were also enhanced. Cabergoline may be an effective and safe alternative agent for men with psychogenic ED.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16728967     DOI: 10.1038/sj.ijir.3901483

Source DB:  PubMed          Journal:  Int J Impot Res        ISSN: 0955-9930            Impact factor:   2.896


  6 in total

Review 1.  Delayed orgasm and anorgasmia.

Authors:  Lawrence C Jenkins; John P Mulhall
Journal:  Fertil Steril       Date:  2015-10-09       Impact factor: 7.329

Review 2.  Testosterone and erectile function: from basic research to a new clinical paradigm for managing men with androgen insufficiency and erectile dysfunction.

Authors:  Abdulmaged M Traish; Irwin Goldstein; Noel N Kim
Journal:  Eur Urol       Date:  2007-02-20       Impact factor: 20.096

3.  Synthesis of novel analogs of cabergoline: improving cardiovascular safety by removing 5-HT2B receptor agonism.

Authors:  Peter I Dosa; Tim Ward; Michael A Walters; Suck Won Kim
Journal:  ACS Med Chem Lett       Date:  2013-02-14       Impact factor: 4.345

Review 4.  Harm Reduction in Male Patients Actively Using Anabolic Androgenic Steroids (AAS) and Performance-Enhancing Drugs (PEDs): a Review.

Authors:  Alex K Bonnecaze; Thomas O'Connor; Cynthia A Burns
Journal:  J Gen Intern Med       Date:  2021-05-04       Impact factor: 6.473

Review 5.  Acromegaly and male sexual health.

Authors:  Gianmaria Salvio; Marianna Martino; Giancarlo Balercia; Giorgio Arnaldi
Journal:  Rev Endocr Metab Disord       Date:  2022-04-01       Impact factor: 9.306

6.  Cabergoline in the Treatment of Male Orgasmic Disorder-A Retrospective Pilot Analysis.

Authors:  Adam B Hollander; Alexander W Pastuszak; Tung-Chin Hsieh; William G Johnson; Jason M Scovell; Christina K Mai; Larry I Lipshultz
Journal:  Sex Med       Date:  2016-03       Impact factor: 2.491

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.